CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted...
Vous n'êtes pas connecté
In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team from UZH and USZ has now discovered that a factor secreted by tumour cells is responsible for the resistance. These findings could pave the way for more effective therapies. Found in the journal Cell Reports Medicine. SUPPORT UNIQUE [...]
CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted...
The Nobel Prize in Medicine was awarded on Monday to two US scientists for discovering microRNA, a previously unknown type of genetic switch which is...
Is diabetes going to be a disease that can finally be treated? This is because another type-1 diabetic patient has been successfully restored using...
Researchers from Weill Cornell Medicine have discovered how COVID-19 can cause new cases of diabetes or worsen existing diabetes in infected...
A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia...
THURSDAY, Oct. 3, 2024 -- Japanese researchers have successfully used a transplant of human stem cells to close a hole in a key part of a monkey's...
Stimulating a key metabolic pathway in T cells can make them work more effectively against tumours when combined with immune checkpoint inhibitor...
Oestrogens are known to drive tumour growth in breast cancer cells that carry its receptors, but a new study by Duke Cancer Institute researchers...
Glioblastoma is the most common and aggressive brain tumor, with patients surviving less than two years after diagnosis. Current treatments could be...
The most comprehensive overview to date of how the immune system reshapes tumour architecture in response to immune checkpoint therapy has been...